Brief: Processa Pharmaceuticals Announces Successful Completion Of Phase 1B Safety Evaluation Of NGC-Cap

Processa Pharmaceuticals

25/01/2024 13:47

Jan 25 (Reuters) - Processa Pharmaceuticals Inc
 PCSA.O :
    * PROCESSA PHARMACEUTICALS ANNOUNCES SUCCESSFUL COMPLETION
OF
PHASE 1B SAFETY EVALUATION OF NGC-CAP IN PATIENTS WITH ADVANCED
CANCER RESULTING IN RECOMMENDED PHASE 2 DOSES
    * PROCESSA PHARMACEUTICALS INC - NGC-CAP WAS BETTER
TOLERATED WITH
POSITIVE PRELIMINARY EFFICACY RESULTS THAN FDA-APPROVED
CAPECITABINE

Source text for Eikon:  ID:nGNX104PsM 
Further company coverage:  PCSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))